Патогенетическое обоснование применения эритропоэтина для коррекции аффективного статуса у больных хронической почечной недостаточностью, находящихся на гемодиализе
Диссертация
Одним из проявлений патологической реактивности у больных ХПН является изменение аффективного статуса. В настоящее время проблема аффективного статуса и психологической реабилитации больных терминальной ХИН занимает передовые позиции в связи со снижением интеркуррентной заболеваемости и смертности, что обусловлено применением современных диализных технологийвведением в клиническую практику новых… Читать ещё >
Список литературы
- Бикбов, Б.Т. Состояние заместительной терапии- больных с хронической почечной недостаточностью в Российской- Федерации в 1998—2007 гг.. / Б. Т. Бикбов, Н. А Томилина // Нефрология и диализ. -2009.-Т. 11, № 3. С. 146−233.
- Бикел, П. Математическая статистика- / П. Бикел, К. Доксам. М.: Финансы и статистика, 1983. — 254 с.
- Блеер, А.Н. Психология деятельности в экстремальных условиях : учеб. пособие для' студ. выс. учеб. заведений / А.Н. Блеер* В. Н. Непопалов, В. Ф. Сопов и др. -М.: Академия, 2008- 256 с.
- Вейн- A.M. Вегетативные расстройства: клиника^ лечение- диагностика-. / A.M. Вейи, Т. К. Вознесенская, О. В. Воробьева и др. М.: Мед. информ. агентство, 2000. — 752 с.
- Ганзен, В.А. Системные описания в психологии / В. А. Ганзен. JI., 1984.-175 с.
- Гарганеева, Н.П. Логистическая регрессия в анализе связи артериальной гипертошш и психических расстройств / Н. П. Гарганеева, В. П. Леонов // Сибирский, мед- журн. 2001. — № 3−4, — С. 42.48. ."•¦" .I.'
- Гланц, С. Медико-биологическая статистика / С. 1 ланц. — М.: Практика, 1999. -438 с.
- Гуревич, К.Я. Человеческий рекомбинантный эритропоэтин (эпокрин) в лечении анемии / К. Я. Гуревич. СПб., 2004. — 64 с.
- Даль, В. Толковый словарь живого великорусского языка : в 4 т. / В. Даль М., 1978−1980. — 683 с.
- Ермоленко, В.М. Эритропоэтин: биологические свойства и применение в клинике / В. М. Ермоленко, А. Ю. Николаев // Терапевт, арх. 1990. -№ 1.- С. 91−106.
- Захаров, Ю.М. Неэритропоэтические эффекты эритропоэтина / Ю. М. Захаров // Рос. физиол. журн. им. И. М. Сеченова. 2007. — Т. 93, № 6. -С. 592−608.
- Захаров, Ю.М. Цитоиротекторные функции эритропоэтина / Ю. М. Захаров // Клинич. нефрология. 2009. — № 1. — С. 16−21.
- Исаев, А. Ш Колебательная активность показателей функциональных систем спортсменов m детей с различным уровнем двигательной активности / А. П. Исаев, Е.В. Быков- А. Р. Сабирьянов и др. -Челябинск, 2005.
- Кобзарь, А.И. Прикладная математическая статистика для инженеров и научных работников / А. И. Кобзарь. М.: Физматлит, 2006. — 816 с.
- Крыжановский, Г. Н. Дизрегуляционная1 патология нервной системы / Г. Н. Крыжановский, Е. И. Гусев. М.: МИА, 2009. — 512 с.
- Ломов, Б.Ф. Методологические и теоретические проблемы психологии / Б. Ф. Ломов М., 1984. — 444 с.
- Люшер, MI Цвет вашего характера / М. Люшер. М.: Вече, Персей, ACT, 1996.-394 с.
- Люшер, М. Оценка личности посредством выбора цвета / М. Люшер. — М.: ЭКСМО-Пресс", 1998. 156 с.
- Михайлов, В.М. Вариабельность ритма сердца: опыт практического применения метода / В. М. Михайлов. ИГМА, 2002. 290 с.
- Мухин, H.A. Хронические прогрессирующие нефропатии и образ жизни современного человека / H.A. Мухин, И. М. Балкаров, C.B. Моисеев и др. // Терапевт, арх. 2004. — № 9. — С. 5−11.
- Николаев, А.Ю. Методы введения рекомбинантного эритропоэтина больным ХПН с анемией на программном гемодиализе / А. Ю. Николаев, C.B. Лашутин, В. М. Ермоленко и др. // Практ. нефрология. -1997. -№ 1.-С. 14−17.
- Петрова, H.H. Качество жизни больных при лечении / H.H. Петрова, H.A. Васильева, С. Л. Гаврик // Нефрология. 1999. — Т. 3, № 1. — С. 8892.
- Петрова, H.H. Концепция качества жизни у больных на заместительной почечной терапии / H.H. Петрова // Нефрология и диализ. 2002. — Т. 4, № 1.-С. 9−11.
- Плохинский, H.A. Математические методы в биологии / H.A. Плохинский. -М.: Мое. Ун-та, 1978. -265 с.
- Реброва, О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA / О. Ю. Реброва. — М.: Медиа Сфера, 2006.-312 с.
- Розен, В.Б. Основы эндокринологии / В. Б. Розен. М., 1994. — 384 с.
- Рябов, С.И. Качество жизни больных, находящихся на лечении гемодиализом / С. И. Рябов, H.H. Петрова, И. А. Васильева // Клинич. медицина. 1996. — Т. 8. — С. 29−31.
- Рябыкина, Г. В. Вариабельность ритма сердца / Г. В. Рябыкина, A.B. Соболев. М.: СтарКо, 1998. — 200 с.
- Смирнов, A.B. Эпидемиология и социально-экономические аспекты хронической болезни почек / A.B. Смирнов, В. А. Добронравов, И. Г. Каюков и др. // Нефрология. 2006. — Т. 10, № 1. — С. 7−13.
- Собчик, JI.H. Модифицированный цветовой тест Люшера: МЦВ -метод цветовых выборов. Практическое руководство / Л. Н. Собчик. — СПб.: Речь, 2002. 100 с.
- Спилбергер, Ч.Д. Концептуальные и методологические проблемы исследования тревоги / Ч. Д. Спилбергер // Стресс и тревога в спорте: сб. науч. ст. М.: ФиС, 1983. — С. 12−24.
- Смулевич, А.Б. Депрессии при соматических и психических заболеваниях: монография. М.: Мед> информ. агентство, 2003. — 432 с.
- Нефрология: руководство для врачей / под ред. И. Е. Тареевой. М.: Медицина, 2000. — 688 с.
- Томилина, Н. Хроническая почечная недостаточность / Н. Томилина // Мед. газета! 2009. — № 52.
- Ханин, Ю.Л. Краткое руководство к применению шкалы реактивной и личностной тревожности / Ю. Л. Ханин, Ч. Д. Спилбергер. Л.: 1976. -18 с.
- Шейман, Д.А. Патофизиология почки / Д. А. Шейман. М.: Бином, 1997.-222 с.
- Шилов, E.H. Хроническая болезнь почек / E.H. Шилов, В. В. Фомин, М. Ю. Швецов // Терапевт, арх. 2007. — №. 6. — С. 75−78.
- Физическая реабилитация больных с терминальной почечной недостаточностью: метод, рекомендации для врачей. СПб., 2009. — 28 с.
- Abraham, H.D. Seroprevalence of hepatitis С in a sample of middle class substance abusers Elecronic resource./ H.D. Abraham, S. Degli-Esposti, L. Marino. 1999. — Mode of access: http://www.osp.unibel.by/obzor/1998/7/3−20.htm.
- Abram, H.S. Suicidal behavior in chronic dialysis patients / H.S. Abram, G.L. Moore, F.B. Westervelt // Am. J. Psychiatry. 1971. — Vol. 127, №> 9. -P. 1199−1204.
- Bauer, G. Eiythropoietin-fromgenestructureto therapeutic: application / C. Bauer // J. Perinat. Med. 1995. — Vol. 23. — P. 77−81.
- Beck, A.T. An inventory for measuring depression / A.T. Beck, G. Hl Ward- M. Mendelson et al. // Arch. Gen. Psychiatry. 1961. — Vol- 41 — P. 561 571.
- Benveniste, H. Glutamate, microdialysis, and cerebral ischemia: lost in translation? / H. Benveniste // Anesthesiology. 2009. — Vol. 110, № 2. — P. 422−425.
- Bernger, M. The sickness impact profil: conceptual formulation' and methodology for development of a health status measure / M. Bernger, R. Bobbitt, S. Kressel et al. // Inf. J. Health Serv. 1978. — Vol. 6. — P. 393 .
- Besson, V.C. Drug targets for traumatic brain injury from poly (ADP-ribose) polymerase pathway modulation / V.C. Besson // Br. J. Pharmacol: 2009. -Vol. 157,№ 5.-P. 695−704:
- Beusterien, K.M. The effects of recombinant human erythropoetin on functional health and well-being in chronic dialysis patients / K. M! Beusterien, A.R. Nissenson, F.K. Port et.al. // J. Am. Soc. Nephrol. 1996. -Vol. 7, № 5.-Pi 763−773.
- Bigger, J.T. Frequency domain, measures of heart periods variability and mortality after myocardial infarction / J. T Bigger, J.L. Fleiss, R.C. Steimman et al. // Circulation. 1992. — Vol. 85, № 1. — P. 164−171.
- Bode-Boger, S.M. Recombinant human erythropoietin enhances vasoconstriction tone via endothelin-1 and8 constrictor prostanoids / S.M. Bode-Bbger, R.H. Boger, M. Kuhn et al. // Kidney Int. -1996. Vol. 50, № 4.-P. 1255−1261.
- Bommer, J. Improved sexual function during recombinant human erythropoietin therapy / J. Bommer, M. Kugel, B. Schwobel et al. //Nephrol. Dial. Transplant. 1990. — Vol. 5, № 3. — P. 204−207.
- Boyette, B.G. Psychosocial adjustment of males on three types of dialysis / B.G. Boyette // Clinical Nursing Research. 1998. — Vol. 7, № 1. — P. 4763.
- Brancaccio, D: Does chronic kidney failure lead- to- mental failure? / D. Brancaccio, R. Damasso- H. Spinnler et al. // Arch. Neurol. 1981. — Vol. 38, № 12.-P. 757−758.
- Brines, M.L. Erythropoietin crosses the blood-brain-barrier to protect against experimental brain*injury / M.L. Brines, P. Ghezzi, S.' Keenan et al. // Proc. Natl. Acad. Sci. USA. -2000:-Vol. 97, №T9. P. 10 526−10 531.
- Brown, W.S. Cognitive function, mood and- P3 latency: effects of the amelioration of anemia in dialysis patients / W.S. Brown, J.T. Marsh, D. Wolcott et al. //Neuropsychologia. 1991. — Vol 29, № 1. -P. 35−45.
- Buckingham- J.K. Comparing three versions of the time tradeoff: time for a change? / J.K. Buckingham, J. Birdsall, J.G. Douglas // Medi Decis. Making. 1996. — Vol 16, № 4. — P. 335−347.
- Byts, N. Erythropoietin: a multimodal neuroprotective agent / Ni Byts, A.L. Siren // Exp. Transl Stroke. Med. 2009. — Vol 1. — 4 p.
- Camacho, A. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death / A. Camacho, L. Massieu // Arch. Med. Res. 2006. — Vol 37, № 1. — P. 11−18.
- Campbell, A. The Quality of American Life / A. Campbell, P.E. Converse, W. Rodgers // Russel Sage Foundation. 1976. — 198 p.
- Cantril, H. The patterns of human Concerns / H. Cantril // Rutgers University Press. 1965.
- Carney, R.M. The relationship between depression and aerobic capacity in hemodialysis patients / R.M. Carney, R.D. Wetzel, J. Hagberg et al. // Psychosomatic Medicine. 1986. — Vol. 48, № 1−2. — P. 143−147.
- Choi, D.W. Ischemia-induced neuronal apoptosis / D.W. Choi // Curr. Opin. Neurobiol. 1996. — Vol'. 6, № 5. — P. 667−672.
- Chou, F.F. Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism / F.F. Chou, J.B. Chen, K.C. Hsieh et al. // Surgery. 2008. — Vol: 143, № 4. — P. 526−532.
- Clement, L. Serum levels of folate and cobalamin are lower in depressed thanin nondepressed/hemodialysis subjects / L. Clement, M. .Boylan, V.G. Miller et al. // J. Ren. Nutr. 2007. — Vol. 17, № 5. — P. 343−349.
- Cournos, F. Use of CBT to treat depression among patients on hemodialysis / F. Cournos, M.D. Golgfinger, S.M. Golgfinger et al. // Psychiatric Services. 2007. — Vol. 58, № 5. — P. 711−713.
- Craven, J.L. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients / J.L. Craven, G.M. Rodin, C. Littlefield // Int. J. Psychiatry. Med. 1988. — Vol. 18, № 4. — P. 365−374.
- Cukor, D. Depression and anxiety in urban hemodialysis patients / D. Cukor, J. Coplan, C. Brown et al. // Clin. J. Am. Soc. Nephrol. 2007. — Vol. 2. -P. 484−490.
- Cukor, D. Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up / D. Cukor, J. Coplan, C. Brown et al. // Clin. J. Am. Soc. Nephrol. 2008. — Vol. 3. — P. 1752−1758.
- Darko, D.F. A critical appraisal of mitogen-induced lymphocyte proliferation in depressed patients / D? F. Darko, N.W. Wilson, J.C. Gillin et ah // Am. J: Psychiatry. 1991. — Vol. 148, № 3. — P. 337−3441
- David- W.H.* Applied" Logistic Regression / W.H. David, 5 L. Stanley. 2nd' edi — Wiley. — 2002. — 392 p.
- D’Andrea- A.D. Erythropoietin receptor. Subunit structure and activation'/ A.D.* D’Andrea, L. I: ZonV/ J. Clin. Invest. 1990. — Voli 86, № 3. — P. 681 687.
- Decker, E. PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure of tooth eruption / E. Decker, A. Stellzig-Eisenhauer, B.S. Fiebig et al. // Ami J. Hum. Genet. 2008. — Vol. 83, № 6. — P. 781−786.
- Delano, B.G. Improvements in quality of life following treatment' with r-HuEPO in. anemic hemodialysis patients / B.G. Delano // Am: J. Kidney Dis. -1989.-Vol. 14, № 2.-P. 14−18.
- Devins, G.M. Illness intrusiveness and quality of life in end-stage renal disease: comparison and stability across treatment modalities / G.M. Devins // Health Psychol. 1990. — Vol. 9. — P. 117.
- Devins, G. M: Psychosocial impact of illness intrusiveness moderated by self concept and age in end-stage renal disease / G.M. Devins, H. Beanlands, H. Mandin et al. // Health Psychol. 1997. — Vol. 16, № 6. — P. 529−538.
- Di Paolo, B. Effects of subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis / B. Di Paolo, A.
- Marini. B. Fiederling et al. II Perit. Dial. Int. 1993. — Vol. 13, № 2. — P.538.540:.
- Doggrell, S.A. A neuroprotective1 derivative of erythropoietin- that: is not erythropoietic-/ S.A. Doggrell // Expert. Opin. Investing. Drugs. 2004. -Vol. 13, № 11. — P. 1517−1519.
- RansuetaM //AmiJiMedi-— 1979!-Vol! 66:.—P! 243−247. 94! Erslev, E. Ji Why the kidney? / E- ji Erslev^ JtCaro, A. Besarab-// Nephron: -1985* Vol! 4E -Pr 213−216h .
- Eschbach, J.W. The- use. of recombinant erythropoietin? in the treatment- of the anemia" of chronic: renal? failure 7 J! WV Eschbach, -N:RL Haley, JiW- Adamson// Ann. N. Y. Acad. Sci. 1989. — Vol. 554. — P. 225−230.
- Eschbach, J.W. Current concepts of anemia management, in chronic renal failure: impact of NKF-DOQI / J. W: Eschbach II Semin. Nephrol. 2000. -Vol. 20, № 4.-P. 320−329.
- European best practice guidelines for the management of anemia in patients with chronic renal failure // Nephrol- DiaK Transplant-.—19 991 — VolLl4V№ 5.-P. 1−50.
- Ferrans, C. Quality of life index: development and psychometric properties / C. Ferrans, M. Powers // Adv. in Nursing Sci. 1985. — Vol. 8. — P. 15.
- Ferrans, C. Satisfaction with health care of hemodialysis patients / C. Ferrans, M. Powers, C. Kasch // Research in Nursing and Health. 1987. -Vol. 10.-P. 367.
- Furuland, H. A randomized controlled trial* of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients / H. Furuland- T. Linde, J. Ahlmen^et al. // Nephrol! Dial. Transplant. 2003. — Vol. 18. — P. 353 361.
- Garthwaite, G. Glutamate Toxicity: An Experimental and Theoretical Analysis / G. Garthwaite, G.D. Williams, J. Garthwaite // Eur. J. Neurosci. -1992. Vol. 4, № 4. — P. 353−360.
- Gelb, S. Cognitive outcome following kidney transplantation / S. Gelb, R.J. Shapiro, A. Hill et al. // Nephrol. Dial. Transplant. 2008. — Vol. 23. — P. 1032−1038.
- Goldberg, N. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin / N.
- Hays, R.D. Development of the kidney disease quality of life (KDQOL) instrument / R.D. Hays, J.D. Kallich- D.L. Mapes et all // Qual. Life. Res. -1994. Vol. 3, № 5. — P. 329−338:
- J.J. Hwang, S.Y. Choi, J.Y. Koh // J. Neurochem. 2002. — Vol. 82, № 4. -P. 894−902.
- Hunt, S. The Nottingham Health profile: subjective status and medical. consultations / S. Hunt, S. Mc Kenna, J. McEven // Soc. Sci. Med. — 1981. — Vol. 15.-P. 221.
- Husebye, D.G. Psychological, social, and somatic prognostic indicators in old patients undergoing long-term dialysis / D.G. Husebye, L. Westlie, TJ. Styrvoky et al. // Arch. Intern. Med. 1987. — Vol. 147, № 11. — P. 1921−1924.
- Irwin, M. Low natural killer cytotoxicity in major depression / M. Irwin // Life Sci. 1987. — Vol. 41, № 18. — P. 2127−2133.
- Iseki, K. Evedence for role of PTH in the reduced pressor response to norepinephrine in chronic renal failure / K. Iseki, S.G. Massry, V.M. Campese // Kidney Int. 1985. — Vol. 28, № 1. — P. 11−15.
- Islam, A. Effect of verapamil of GRF-induced abnormalities in phospholipid contents of brain synaptosomes / A Islam, M. Smogerzewski, S.G. Massry // Proc. Soc. Exp. Biol- Med. 1990. — Vol. 194. — P. 16−20.
- Israel, M: Depression in dialysis patients: a review of psychological factors / M. Israel'// Can. J. Psychiatry. 1986. — Vol. 31, № 5. — P: 445−451.
- Jacobs, C. European best practice guidelines 5 target haemoglobin / C. Jacobs, W.H. Horl, I.C. Macdougall et al. // Nephrol. Dial. Transplant. -2000. Vol. 15, № 4. p. 15−19.
- Jacobs, C. Renal replacement therapy by hemodialysis: an overview / C. Jacobs // Nephrol. Ther. 2009. — Vol. 5, № 4. — P. 306−312.
- Jaguet, K. Erythropoietin and VEGF exhibit equal angiogenic potential / K. Jaguet, K. Krause, M. Tawakol-Khodia et al. // Microvasc. Res. 2002. -Vol. 64, № 2.-P. 326−333.
- Jiang, W. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure / W. Jiang, W.R. Hathaway, S. Larsen et al. // Am. J. Cardiol. 1997. — Vol. 80, № 6. — P. 808−811.t
- Julius, M. A comparison of employment rates of patients treated- with continuous ambulatory peritoneal dialysis vs in center hemodialysis / M. Julius, J. Kneisley, P. Carpentier-Alting et al. // Arch. Intern. Med: 1989. -Vol. 149:-P. 839:
- Juppner, H. G-proteinlinked receptor for parathyroid hormone and parathyroid hormone-related peptide / H. Juppner, A. Abou Samra, M.A. Freeman// Science. 1991. — Vol. 254. — P. 1024−1026.
- Kaplan De Nour, A. Stresses and, reactions of professional" hemodialysis staff / A. Kaplan De Nour // Dial. Transplant. 1984. — Vol*. 13. — P! 137.
- Kaupke, C.J. Effect of erythrocyte mass on arterialblood pressure indialysis patients receiving maintenance erythropoietin therapy / C. J! Kaupke, S. Kim, N.D. Vaziri // J. Am. Soc. Nephrol: 1994. — Vol. 4, № 11. — P. 1874−1878.
- Kimmel, P.L. Multiple measurements of depression predict mortality, in a longitudinal study of chronic hemodialysis outpatients / P.L. Kimmel, R.A. Peterson, K.L. Weihs et al. // Kidney Int. 2000. — Vol. 57, № 5. — P. 20 932 098.
- Kimmel, P.L. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived / P.L. Kimmel, R.A. Peterson // Clin. J. Am. Soc. Nephrol. 2006. — Vol. 1. — P. 349−352.
- Koh, J.Y. The role of zinc in selective neuronal death after transient global cerebral ischemia / J.Y. Koh, S.W. Suh, B J. Gwag et al. // Science. 1996. -Vol. 272, № 5264. — P. 1013−1016.
- Kohagura, K. rHuERO dose inversely correlated with" the number of circulating CD34+ cells in maintenance hemodialysis patients / K. Kohagura, Y. Ohya, S. Miyagi et al. // Nephron. Clin. Pract. 2008. — Vol. 108, № 1.-P. 41−46.
- Kramer, L. Beneficial effect of renal transplantation* on cognitive brain function / L. Kramer, C. Madl, F. Stockenhuber et al. // Kidney Int. 1996. -Vol. 49, № 3.-P. 833−838.
- Kurella, T. Ml Cognitive impairment in chronic kidney disease / T.M. Kurella, G.M. Chertow, J. Luan et al. I I J. Am. Geriatr. Soc. 2004. — Vol. 52,№ 11.-P. 1863−1869.
- Kurella, T.M. Suicide in the United" States end-stage renal disease program / T.M. Kurella, P.L. Kimmel, B.S. Young et al. // J. Am. Soc. Nephrol: -2005.-Vol. 16, № 3.- P. 774−781.
- Kurella, T.M. Kidney function and cognitive impairment in, US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study / T.M. Kurella, V. Wadley, K. Yaffe et al. // Am. J. Kidney Dis. -2008. Vol. 52, № 2. — P. 227−234.
- Kutlay, S. Recognition of neurocognitive dysfunction in chronic hemodialysis patients / S. Kutlay, G. Nergizoglu, N. Duman et al. // Ren. Fail. 2001. — Vol. 23, № 6. — P. 781−787.
- Kutner, N. End-stage renal disease treatment modality and patients' quality of life. Longitudinal assessment / N. Kutner, D. Brogan, M. Kutner // Am. J. Nephrol. 1986. — Vol. 6. — P. 396.
- Langenfeld, M.R. Is endogenous erythropoietin a pathogenetic factors in the development of essential hypertension? / M.R. Langenfeld, R. Veelken, H.P. Schobel et al. // Nephrol. Dial. Transplant. 1997. — Vol. 12, № 6. — P. 1155−1160.
- Lappin, T. The cellular biology of erythropoietin^ receptors / T. Lappin // Oncologist. 2003. — Vol. 8, № 1. — P. 15−18:
- Laupacis, A. Canadian Erytropoetin- Study Group. Association^ between recombinant human" erytropoetin and quality of life and exercise capacity of patients receiving hemodialysis-/ A. Laupacis // Br. Med. J: 1990: — Vol. 300:-P. 573.
- Laupacis, A. Canadian erythropoetin study group. The use of generic and specific Quality-of-life measures in hemodialysis patients treated with erytropoetin / A. Laupacis, C. Wong, D. Churchill // Controlled Clinical.-1991.-Vol. 12, № l.-P. 168.
- Lee, J.M. Zinc translocation accelerates infarction after mild’transient focal ischemia / J.M. Lee, G. J: Zipfel, K.H. Park et al. // Neuroscience. 2002. -Vol. 115- № 3- - P. 871−878.
- Levin, A. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin / A. Levin, C.R. Thompson, J. Ethier et al." // Am. J. Kidney Dis. 1999. — Vol. 34, № 1. — P. 125−134.
- Leung, K.C. Psychosocial aspects in renal patients / K.C. Leung // Peritoneal Dialysis International. 2003. — Vol. 23, № 2. — P. 90−94.
- Lillevang, S. The quality of life for hemodialysis patients before and, after erythropoetin treatment. A double-blind, randomized placebo-controlled investigation / S. Lillevang, F. Bangsgaard Pedersen // Ugeskr. Laeger. -1990-Vol. 152.-P. 2999.
- Lippin, Y. Human erythropoietin gene therapy for patients with chronic renal failure / Y. Lippin, M. Dranitzki-Elhalel, E. Brill-Almon et al. // Blood. 2005. — Vol. 106, № 7. — P. 2280−2286.
- Lipton, P. Ischemic cell death in brain neurons / P. Lipton // Physiol. Rev. -1999. Vol. 79, № 4. — P. 1431−1568.
- Lopes, A.A. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe / A.A. Lopes, J. Bragg, E. Young et al. // Kidney Int. 2002. — Vol. 62, № 1. — P. 199−207.
- Luscher, M. The Luscher Colour Test / M. Luscher. Sydney, 1983. -207 p.
- Macdougall, I.S. Coagulation studies and fistula^ blood-flow during erythropoietin therapy in hemodialysis-patients / I.S. Macdougall, M.E. Davies, I. Hallett et al. // Nephrol. Dial. Transplant. 1991. — Vol: 6, № 11. -P. 862−867.
- Macdougall, I.S. Role of uremic toxins in exacerbating anemia in renal failure // Kidney. Int. Suppl. 2001. — Vol. 78. — P. 67−72.
- Madan, P. Cognitive impairment in chronic kidney disease / P. Madan, O.P. Kalra, S. Agarwal et al. // Nephrol. Dial: Transplant. 2007. — Vol. 22, № 2. P. 440−444.
- Mahoney, C.A. Uremic encephalopathies: clinical, biochemical, and experimental features / C.A. Mahoney, A.I. Arieff // Am. J. Kidney Dis. -1982. Vol. 2, № 3. — P. 324−336.
- Marti, H.H. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia / H.H. Marti, M. Bernaudin, E. Petit et al. // News Physiol. Sci. 2000. — Vol. 15. — P. 225−229.
- Mason-Garcia, M. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin / M. Mason-Garcia, B.S. Beckman, J.W. Brookins et al. // Kidney. Int. 1990. — Vol. 38, № 5. — P. 969−975.
- Mayer, G- Anaemia and reduced exercise capacity in patients on chronic haemodialysis / G. Mayer, J. Thum, H. Graf// Clin. Sci. 19 891 — Vol: 76, № 3. -P: 265−268.
- McMahon, L. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human crytropietin / L. McMahon. J. Dawbom // Am. J. Nephrol. 1992. — Vol: 12.-P. 162. .
- Milano, M? Erythropoietin and neuroprotection: a therapeutic perspective / M: Milano, R. Collomp // J: Oncol: Pharm: Pract. 2005: — Vol'. 11, № 4. -P. 145−149. ,
- Miranda Sde, P. Cardio-renal syndrome: pathophysiology and treatment / P. Miranda? Sde, R. N- Macedbj G: B: Silva Junior efe al: II Rev. Assoc: Med. Bras,-2009: Vok55, № 1.-P. 89−94-
- Risk factors for hepatitis C virus infection in united states blood donors Electronic resoursce. / E.L. Murphy, S.M. Bryzman. 2000. — Mode of access: http://www.hepatitinfo.ru/vgO 100/5.htm.
- Morris, K.P. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anemia / K.P. Morris, J. Sharp, S. Watson et al. // Arch. Disease in Childhood. 1993. — Vol. 69. — P. 580−586:
- Muirhead, N. Erythropoietin for anemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group) / N. Muirhead, A. Laupacis, C. Wong // Nephrol. Dial. Transplant. 1992. -Vol. 7, № 8.-P. 811−816.
- Ni, Z. Derangements in acetylcholine metabolism-in brain>synaptosomes in chronic renal failure / Z. Ni- M. Smogorzewski- S.G. Massry // Kidney Int. -1993. Vol. 44, № 3. — P. 630−637.
- Nishimura, M. Association-between cardiovascular autonomic neuropathy and left ventricular hypertrophy in* diabetic* haemodialysis patients / M. Nishimura, T. Hashimoto, H. Kobayaslii> et al. // Nephrol. Diall Transpl. -2004. Vol'. 19r — P: 2532−2538.
- Nissenson, A.R. Recombinant human erytropoetin: impact on brain" and cognitive function, exercise tolerance, sexual potency and* quality of life / A.R. Nissenson // Semin: Nephrol. 1989. — Vol. 9, № 2. — P. 25.
- Nissenson- A. R". Cognitive function" in dialysis patients: impact of erytrpoetin alfa / A.R. Nissenson // New Directions in Anaemia. 1991. -Vol. 2.-P. T.
- Nissenson, A.R. Epoetin and cognitive function / A.R. Nissenson // Am. J. Kidney Dis. 1992: — Vol. 20, № 1. — P. 21−24.
- Nicholls, D. The release and uptake of excitatory amino acids / D. Nicholls, Di Attwell // Trends. Pharmacol. Sci. 1990. — Vol. 11, № 11. -P: 462−468.
- NKF-DOQI Clinical Practice Guidlines for Peritoneal Dialysis Adequacy // National Kidney Foundation. 1997. — №. 2. — P. 69−136.
- NKF-DOQI Work Groop. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure // Am. J. Kidney Dis. 1997. -Vol. 30, № 3.-P. 192−240.
- Noshita, N. Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice / N. Noshita, T. Sugawara, A. Lewen et al. // Stroke. 2003. — Vol. 34, № 6. — P. 1513−1518.
- Nulsen, R.S. Prevalence of cognitive impairment in patients attending pre-dialysis clinic / R.S. Nulsen, M.M. Yaqoob, A. Mahon et al. // J. Ren. Care. 2008. — Vol. 34, № 3. — P. 121−126.
- Polkey, M.I. Respiratory aspects of neurological" disease / M.I. Polkey, R.A. Lyall, J. Moxham et ah // J. Neurol. Neurosurg. Psychiatry. 1999. — Vol. 66, № 1. -P: 5−15.
- Quality of life assessment: an annotated bibliography. Geneva, 1994.
- Radermacher, J. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system / J. Radermacher, H.M. Koch // Clin. Nephrol. 1995. -№ 1. p. 56−60.
- Ribatti, D. Human- erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo / D. Ribatti, M. Presta, A. Vacca et al. // Blood. 1999. — Vol. 93, № 8. — P. 2627−2636.
- Rehncrona, S. Brain lactic acidosis and ischemic cell damage: 1. Biochemistry and neurophysiology / S. Rehncrona, I. Rosen, B.K. Siesjo // J. Cereb. Blood Flow Metab. 1981. — Vol. 1, № 3. — P. 297−311.
- Revicki, D.A. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients /
- D.A. Revicki, R.E. Brown, D.H. Feeny et al. // Am. J. Kidney Dis. 1995. -Vol. 25, № 4.-P. 548−554.
- Rohl, J.E. Quantitative EEG findings in patients with chronic renal failure / J.E. Rohl, L. Harms, W. Pommer // Eur. J. Med. Res. 2007. — Vol. 12, № 4.-P. 173−178.
- Rossau, C. D: Risk factors for suicide in patients with schizophrenia: nested case-control study Elecronic resource. / C.D. Rossau, P.B. Mortensen. -1998. Mode of access: http://www.osp.unibel:bv/obzor/1998/2/3−7.htm:'
- Saele, K. Cognitive failure in- terminal kidney disease / K. Saele, H. Sonnesyn, E. Svarstad-et al. // Tidsskr. Nor. Laegeforen. 2009. — Vol.129, № 4: -Pi 296−299:
- Sakanaka" M. In vivo evidence that erythropoietin protects neurons from ischemic damage*/ Ml Sakanaka, T.C. Wen, S. Matsuda et al. // Proc. Natl.
- Acadi Sci. USA. 1998. — Vol. 95, № 8: — Pi 4635−4640.
- Sensky, T. Psychosomatic aspects of end-stage renal’failure / T. Sensky// Psychother. Psychosom. 1993. — Vol. 59, № 2. — P.56−68.
- Siesjo, B.K. Mechanisms of ischemic brain damage / B.K. Siesjo // Crit. Care. Med. 1988. — Vol. 16, № 10. — P. 954−963.
- Siren, A.L. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress / A.L. Siren, M. Fratelli, M. Brines et al. // Proc. Nat. l Acad. Sci. USA. 2001. — Vol. 27, № 98. — P. 4044−4049.
- Siren, A.L. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin / A.L. Siren, K. Radyushkin, S. Boretius et al. // Brain. 2006. — Vol. 129, № 2. — P. 480−489.
- Smogorzewski, MUi PTH, chronic renal failure and* myocardium? / MiJi Smogorzewski //Miner. ElectroliMetab.-1995: Vol. 21. P. 55−62.
- Smogorzewski, M. JL Function «and- metabolism of- brain synaptosomes in chronic renal failure / M.J. Smogorzewski, Z. Ni- S.G. Massiy // Artif Organs. 1995. — Vol. 19, № S. -P. 795−800.
- Smogorzewski- Mi J: Central nervous dysfunction im uremia- / M.J. Smogorzewski // Am: Jt Kidney Dis. 200E — Vol: 38, № 4:.-P. 122−128.
- Smogorzewski, M. J*. Altered acetylcholine metabolism of brain in uremia: role of secondary hyperparathyroidism / M.J. Smogorzewski, S.G. Massry // J. Ren. Nutr. 2008- - Vol. 18, № l.-p. 122−126.
- Soskolne, V. The psychosocial adjustment of patients and spouses to dialysis treatment/V. Soskolne, A. KaplanDeNour// Soc. Sci. Med. 1989. — Vol. 29.-P. 497.
- Souheaver, G.T. Neuropsychological patents in uremia / G.T. Souheaver, J.J. Ryan, A.S. DeWolfe // J. Clin. Psychol. 1982. — Vol. 38, № 3. — P. 490−496.
- Stein, M. Stress, depression, and the immune system / Ml Stein // J. Clin. Psychiatry. 1989. — Vol. 50, № 35−40. — P. 41−42.
- Steinberg, H. Erythropoietin and visual hallucinations in patients on dialysis / H. Steinberg, S.M. Saravay, N. Wadhwa et al. // Psychosomatics. 1996. -Vol. 37.-P. 556−563.
- Stohlawetz, P.J. Effects of erythropoietin on- platelet reactivity and thrombopoiesis in*human / PJ. Stohlawetz, L. Dzirlo, N. Hergovich et al. // Blood. 2000. — Vol. 95, № 9. — P. 2983−2989.
- Stout, J. Sexual and marital relationships and dialysis the patient’s viewpoint / J. Stout, J. Auer, J. Kincey et al. // Pent. Dial. Bull. — 1987. -Vol. 7.-P. 97.
- Strunk, T. Erythropoietin inhibits cytokine production of neonatal and. adult leukocytes / T. Strunk, C. Hartel, P. Temming et al. // Acta. Paediatr. -2008.-Vol. 97, № 1.-P. 16−20.
- Sugawa, M. Effects of erythropoietin on glial cell development- oligodendrocyte maturation and astrocyte proliferation / M. Sugawa, Y. Sakurai, Y. Ishikawa-Ieda et al. // Neurosci. Res. 2002. — Vol. 44, № 4. -P. 391−403.
- Sujic, R. Cognitive disorders in patients with chronic renal insufficiency / R. Sujic, M. Vukovic // Vojnosanit Pregl. 1997. — Vol. 54, № 6. — P. 555−563.
- Sunder-Plassmann, G. Effect of erythropoietin on cardiovascular diseases / G. Sunder-Plassmann, W.H. Horl // Am. J. Kidney Dis. 2001. — Vol. 38, № 4.-P. 20−25.
- Taoufik, E. TNF receptor I sensitizes neurons to erythropoietin and’VEGF-mediated neuroprotection after ischemic and excitotoxic injury / E. Taoufik, E. Petit, D. Divoux et al. // Proc. Natl. Acad. Sci. USA. — 2008. — Vol. 22, № 105.-P. 6185−6190:
- Temple, R.M. Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients / R.M. Temple, S.J. Langan- I.J. Deary et al. // Nephrol. Dial. Transplant. 1992 — Vol. 7. — P. 240−245.
- Thomas, L. Cardiovascular biology of the parathyroid hormone-related proteins. Endocrinology of cardiovascular function / L. Thomas, P.D. Clemens, A. Levin edal: // Academic Publishers. 1998. — P. 237−254'.
- Thuraisingham, R.C. Left ventricular hypertrophy in early renal failure / R.C. Thuraisingham, B. Tucker, G.W. Lipkin et al. // RA-BAPN. 1993. -859 p.
- Topczewska-Bruns, Ji Kynurenine metabolism in central nervous system in experimental* chronic renal failure / J. Topczewska-Bruns, D. Pawlak, A. Tankiewicz et al. // Adv. Exp. Med. Biol. 2003 — Vol. 527. — P. 177−182.
- Trzonkowski, P. Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients / P. Trzonkowski, A. Debska-Slizien, E. Szmit et al. // Nephrol. Dial. Transplant: 2005 — Vol. 20, № 2.-P. 367−376.
- Tucker, C. Quality' of life of patients on in-center hemodialysis versus continuous ambulatory peritoneal dialysis / C. Tucker, R. Ziller, W. Smith et al. // Pent. Dial. Int. 1991. — Vol. 11. — P. 341.
- Vesey, D.A. Erythropoietin protects against ischaemic acute renal injury / D.A. Vesey, C. Cheung, B. Pat et al. // Nephrol. Dial. Transplant. 2004. -Vol. 19, № 2.-P. 348−355.
- Vaziri, N.D. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal’failure / N. D*. Vaziri, X.J. Zhou, F. Naqvi et al. // Am. J. Physiol. 1996. — Vol. 271, № 1-. — P. 113−122'.
- Wadhwa, N. Erythropoietin and quality of life in ESRD patients / N. Wadliwa, R. Friend, N. Russo et al. // J. Am. Soc. Nephrol. 1991. — Vol. 2. -P. 390.
- Wald, M.R. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways / M.R. Wald, E.S. Borda, L. Sterin-Borda // J. Cell Phisiol. 1996. — Vol. 167, № 3. — P. 461−468.
- Wallnofer, H. Der Luscher-Farbtest zur Diagnose des vegetativen Verhaltens / H. Wallnofer // Arzt. Prax. 1966. — Volt 18, № 70. — P. 2348−2352.
- Wang, G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia / G.L. Wang, G.L. Semenza // Proc. Natl. Acad. Sci. USA. 1993. — Vol. 90, № 9. — P. 4304−4308.
- Wolcott, D: Quality of life in chronic dialysis patients: a critical comparison of continuous ambulatory peritoneal dialysis and hemodialysis / D. Wolcott, A. Nissenson*// Am- J:.Kidney Dis. 1988. — Vol. 9. — P: 4021
- Wussow, U. Is the renal' production*of eiythropoietimcontrolledlby thebraim stem? / U. Wussow, J. Klaus, HIPageM Am. J: Physiol: EndocrinollMetab. 2005. — Vol. 289. — P. 82−86.. >
- Yamaji, R. Brain? capillary endothelial? cells express two forms: of erythropoietin receptor mRNA / R. Yamaji, T. Okada, M. Moriya et al. // Eur. J. Biochenv. 1996. -Vol. 239, № 2. — P. 494−500.
- Yanagida-! E: H., Limitation of psychological tests im a dialysis population / E.H. Yanagida- J: Streltzer // Psychosomatic Medicine: 1979. — Vol. 41, № 7.-P. 557−565.
- Yoo, J.Y. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed! spinal cultures / J1Y. Yoo, Y.J. Won, J.H. Lee’et all// J. Neurosci. Res. 2009. — Vol. 87, № 1. — P. 150 163.
- Yerkes, R. The relation of strength of stimulus to rapidity of habitformation / R. Yerkes, J. Dodson // J. Comp. Neurol. Psychol. 1998. — № 18. — P. 459 482.
- Yu, X. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse / X. Yu, C.S. Lin, F. Costantini et al. // Blood. 2001. — Vol. 98, № 2. — P. 475−477.
- Zweig, M.H. ROC Plots: a fundamental evaluation tool in clinical medicine / M.H. Zweig, G. Campbell // Clinical Chemistry. 1993. — Vol. 39, № 4. -P. 561−577.